Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain

被引:53
|
作者
Petzold, Axel
Shaw, Gerry
机构
[1] UCL, Dept Neuroimmunol, Inst Neurol, London WC1N 3BG, England
[2] Univ Florida, Coll Med, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32611 USA
关键词
neurofilament; NfH; NF-H; pNfH; biomarker;
D O I
10.1016/j.jim.2006.09.021
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Recent studies suggest that the quantification of neurofilament subunits in cerebrospinal fluid (CSF), blood and amniotic fluid may reflect neuroaxonal damage and be of high clinical value. The present study aims to cross-validate two different independently developed ELISA techniques for the quantification of the phosphorylated axonal forms of the neurofilament heavy chain (pNfH). Methods: The London ELISA method is based on barbitone buffer and the commercially available SM135 capture antibody. The Gainesville method uses Tris-buffered saline (TBS) and an affinity purified chicken polyclonal capture antibody (C-pNfH). Coded CSF from 50 patients with neurological diseases were analyzed in duplicate by both laboratories, each using both ELISA methods, but with each lab using their own detection antibody, tertiary antibody and chromogen. Methods were compared using Bland Altman plots. Correlation and regression analyses were used to allow for transformation of values between both methods. Results: The Bland-Altman plots demonstrated that 96% of all samples fell into the narrow 95% limits of agreement (0.04 units of OD). There was a high correlation (Spearman R = 0.92, p < 0.0001 and Pearson R = 0.98, p < 0.0001) between the Gainesville (1) and the London (X) method with Y=0.132+1.104*X. The previously determined upper reference limit of 0.73 mg/l (London method) corresponds to 0.94 mg/l for the Gainesville method. CSF pNfH levels above the reference limit were observed in patients with encephalitis, encephalomyelitis, hydrocephalus, subarachnoid haemorrhage, spino-muscular atrophy, stroke and cancer with both methods agreeing in all cases. Conclusion: The two assays are in excellent agreement, suggesting that pNfH, which has a number of unusual protein chemical features, may be the biomarker of choice for the routine and robust detection of axonal injury and degeneration in both research and clinical contexts. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [1] Cross-validation of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain
    Petzold, A.
    Shaw, G.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S60 - S60
  • [2] A specific ELISA for measuring neurofilament heavy chain phosphoforms
    Petzold, A
    Keir, G
    Green, AJE
    Giovannoni, G
    Thompson, EJ
    JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 278 (1-2) : 179 - 190
  • [3] Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels
    Kusnierova, Pavlina
    Zeman, David
    Hradilek, Pavel
    Cabal, Martin
    Zapletalova, Olga
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (07)
  • [4] Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
    Gresle, M. M.
    Liu, Y.
    Dagley, L. F.
    Haartsen, J.
    Pearson, F.
    Purcell, A. W.
    Laverick, L.
    Petzold, A.
    Lucas, R. M.
    Van der Walt, A.
    Prime, H.
    Morris, D. R.
    Taylor, B. V.
    Shaw, G.
    Butzkueven, H.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1209 - 1213
  • [5] Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis
    Li, Siyuan
    Ren, Yuting
    Zhu, Wenjia
    Yang, Fei
    Zhang, Xiaolan
    Huang, Xusheng
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 367 : 269 - 274
  • [6] Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis
    Kaiserova, M.
    Grambalova, Z.
    Otruba, P.
    Stejskal, D.
    Vranova, H. Prikrylova
    Mares, J.
    Mensikova, K.
    Kanovsky, P.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (04): : 360 - 364
  • [7] A PHOSPHORYLATED NEUROFILAMENT HEAVY CHAIN INDICATES THE SEVERITY OF AXONAL NEUROPATHY
    Chen, X-J
    Zhang, X. U.
    Xu, H.
    Zhu, D-Q
    Xi, Zhang
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 : 22 - 22
  • [8] Serum levels of phosphorylated neurofilament heavy chain differ between multiple sclerosis clinical group types
    Frese, K.
    Patel, P.
    Kamma, E.
    Becquart, P.
    Traboulsee, A.
    Carruthers, R. L.
    Devonshire, V.
    Sayao, A. -L.
    Schabas, A.
    Moore, G. W.
    Vavasour, I. M.
    Laule, C.
    Quandt, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 782 - 782
  • [9] Phosphorylated neurofilament heavy chain: a potential diagnostic biomarker in amyotrophic lateral sclerosis
    Heckler, Ilana
    Venkataraman, Iswariya
    JOURNAL OF NEUROPHYSIOLOGY, 2022, 127 (03) : 737 - 745
  • [10] Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis
    Zecca, Chiara
    Dell'Abate, Maria Teresa
    Pasculli, Giuseppe
    Capozzo, Rosa
    Barone, Roberta
    Arima, Serena
    Pollice, Alessio
    Brescia, Vincenzo
    Tortelli, Rosanna
    Logroscino, Giancarlo
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (13) : 3608 - 3615